You are here

What’s the Stem Cells Buzz this Week? – Pericyte-mediated Cardiovascular Healing, MSC-Derived Microvesicles, Allogeneic Stem Cell Therapy for RDEB, and MSC-aided Islet Transplantation!




The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond! 


Reviewing the Potential for Pericytes in Cardiovascular Healing

Pericytes, the mural cells of blood microvessels, represent a promising therapeutic candidate for non-revascularizable coronary artery disease (CAD) due to their angiogenic capacities and their “robustness” in response to a hypoxic environment. A new STEM CELLS review article from the Paolo Mededdu lab (University of Bristol, UK) now summarizes the rationale behind and the current progress towards pericyte‐based cell therapy. Cathery et al. also consider different sources of pericytes and harvesting pericytes from cardiovascular surgery and go onto discuss preclinical animal models of myocardial ischemia and current practices to upgrade the production protocol for translation to the clinic.

MSC-Derived Microvesicles Stabilize Lung Endothelium

Previous studies from the lab of Jae‐Woo Lee (University of California San Francisco, USA) suggested that mesenchymal stem cell (MSC)-derived microvesicles (MVs) reduced lung inflammation, protein permeability, and pulmonary edema in endotoxin‐induced acute lung injury in mice. In their new study, Hu et al. now demonstrate that MSC-MVs restore protein permeability across injured human lung microvascular endothelial cells (HLMVECs) by increasing Ang1 transcription and secretion into the injured endothelium, which prevents “actin stress fiber” formation. For more on this story, head over to STEM CELLS Translational Medicine.

Allogeneic Stem Cell Therapy for Recessive Dystrophic Epidermolysis Bullosa

Previous studies from the laboratory of Mitchell S. Cairo (New York Medical College, Valhalla, New York, USA) highlighted a role for human cord blood‐derived unrestricted somatic stem cell treatment to promote wound healing and ameliorate the blistering phenotype in a recessive dystrophic epidermolysis bullosa (RDEB) mouse model. In their new study, Liao et al. demonstrate significant therapeutic benefits of human allogeneic placental‐derived stem cell (HPDSC) treatment and establish that HPDSCs migrate to the skin and gastrointestinal tract to significantly improve the adherence of the epidermis to the dermis of the skin. See STEM CELLS Translational Medicine now for more on this exciting new study!

MSCs in Islet Transplantation

We end this week with a Perspective from the laboratory of Peter M. Jones (King's College London, UK), who discuss how factors secreted from mesenchymal stem cells (MSCs) hold the potential to improve islet graft functional survival and transplantation outcomes as a means to cure Type 1 diabetes. Specifically, they report on the potential for the application of cell‐free cocktails of MSC‐derived products to treat islets before transplantation. See STEM CELLS Translational Medicine now for what promises to be a fascinating read.

That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!